Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2014 2
2016 1
2017 1
2018 2
2019 1
2020 4
2021 3
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-reactive antibodies evolve from non-binding and autoreactive precursors.
Mazor RD, Nathan N, Gilboa A, Stoler-Barak L, Moss L, Solomonov I, Hanuna A, Divinsky Y, Shmueli MD, Hezroni H, Zaretsky I, Mor M, Golani O, Sabah G, Jakobson-Setton A, Yanichkin N, Feinmesser M, Tsoref D, Salman L, Yeoshoua E, Peretz E, Erlich I, Cohen NM, Gershoni JM, Freund N, Merbl Y, Yaari G, Eitan R, Sagi I, Shulman Z. Mazor RD, et al. Among authors: tsoref d. Cell. 2022 Mar 31;185(7):1208-1222.e21. doi: 10.1016/j.cell.2022.02.012. Epub 2022 Mar 18. Cell. 2022. PMID: 35305314 Free article.
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew Y, Kim JW, Penson RT, O'Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, De Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S; MEDIOLA Investigators. Drew Y, et al. Among authors: tsoref d. Clin Cancer Res. 2024 Jan 5;30(1):50-62. doi: 10.1158/1078-0432.CCR-23-2249. Clin Cancer Res. 2024. PMID: 37939124 Free PMC article. Clinical Trial.
Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis.
Pomerantz A, Tsoref D, Grubstein A, Wadhawker S, Rapson Y, Gadiel I, Goldvaser H, Feldhamer I, Hammerman A, Shochat T, Sharon E, Kedar I, Yerushalmi R. Pomerantz A, et al. Among authors: tsoref d. Breast Cancer Res Treat. 2022 Jun;193(2):507-514. doi: 10.1007/s10549-021-06498-9. Epub 2022 Apr 7. Breast Cancer Res Treat. 2022. PMID: 35391652 Free PMC article.
Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcome.
Ben-Zion Berliner M, Yerushalmi R, Lavie I, Benouaich-Amiel A, Tsoref D, Hendler D, Goldvaser H, Sarfaty M, Rotem O, Ulitsky O, Siegal T, Neiman V, Yust-Katz S. Ben-Zion Berliner M, et al. Among authors: tsoref d. Breast Cancer Res Treat. 2021 Jan;185(2):423-432. doi: 10.1007/s10549-020-05959-x. Epub 2020 Oct 10. Breast Cancer Res Treat. 2021. PMID: 33037977
3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial.
Yerushalmi R, Bargil S, Ber Y, Ozlavo R, Sivan T, Rapson Y, Pomerantz A, Tsoref D, Sharon E, Caspi O, Grubsrein A, Margel D. Yerushalmi R, et al. Among authors: tsoref d. Carcinogenesis. 2020 Oct 15;41(10):1395-1401. doi: 10.1093/carcin/bgaa050. Carcinogenesis. 2020. PMID: 32458980 Free PMC article. Clinical Trial.
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
Lewin R, Sulkes A, Shochat T, Tsoref D, Rizel S, Liebermann N, Hendler D, Neiman V, Ben-Aharon I, Friedman E, Paluch-Shimon S, Margel D, Kedar I, Yerushalmi R. Lewin R, et al. Among authors: tsoref d. Breast Cancer Res Treat. 2016 Jun;157(3):511-6. doi: 10.1007/s10549-016-3836-6. Epub 2016 May 25. Breast Cancer Res Treat. 2016. PMID: 27225387
18 results